Literature DB >> 17592982

Complications arising in the final year of life in men dying from advanced prostate cancer.

Richard Khafagy1, David Shackley, Joanne Samuel, Kieran O'Flynn, Chris Betts, Noel Clarke.   

Abstract

OBJECTIVES: There are sparse anecdotal data on complications occurring in the final year of life in men dying of prostate cancer. The study aim was to record such data together with the interventions necessary and subsequent outcomes.
METHODS: Using an established prostate cancer database detailing all men presenting to a single institute with the disease, case notes and the hospital electronic databases were examined from men diagnosed with hormone refractory prostate cancer that went on to die of their disease between January 1, 1995 and December 31, 2002 (n=226). The frequency of complications and subsequent therapeutic interventions within the final 12 months of life were recorded together with the effect of those interventions.
RESULTS: The most common incident complications arose in the lower urinary tract. Overall, 27% (61 men) had lower urinary tract complications (LUTS), 12% (n=27) had progressive renal failure, 10% (n=23) became anemic, and 9% (n=21) had persistent bone pain despite analgesia. Fourteen percent (n=37) had skeletal-related complications (including bone pain, fractures, and cord compression). One hundred four men (46%) had a cancer-related complication with 25% (n=56) requiring related intervention(s). An improvement was observed in over three quarters of men (76%) who received an intervention. These included "channel" transurethral resection of prostate (TURP) (14% of men; n=32), long-term urethral or suprapubic catheterization (7.5%; n=17), blood transfusion (7.5%; n=17), external beam radiation for pain (4.9%; n=11), nephrostomy tube or ureteric stent insertion (2.7%; n=6), and fracture fixation (2.2%; n=5).
CONCLUSIONS: The commonest adverse events in the final year of life in men dying of advanced prostate cancer are those of LUTS, renal failure, anemia, and bone pain with almost half of men developing at least one of these. The majority of men who had interventions demonstrated a subjective or objective improvement.

Entities:  

Mesh:

Year:  2007        PMID: 17592982     DOI: 10.1089/jpm.2006.0185

Source DB:  PubMed          Journal:  J Palliat Med        ISSN: 1557-7740            Impact factor:   2.947


  13 in total

Review 1.  [Treatment of specific complications of locally advanced prostate cancer].

Authors:  F C von Rundstedt; A S Brandt; D Lazica; M J Mathers; S Roth
Journal:  Urologe A       Date:  2008-11       Impact factor: 0.639

2.  Analysis of the risk factors for myelosuppression after concurrent chemoradiotherapy for patients with advanced non-small cell lung cancer.

Authors:  Nan Jiang; Xiao-Cen Chen; Yue Zhao
Journal:  Support Care Cancer       Date:  2012-08-31       Impact factor: 3.603

3.  Anaemia and thrombocytopenia in patients with prostate cancer and bone metastases.

Authors:  Carsten Nieder; Ellinor Haukland; Adam Pawinski; Astrid Dalhaug
Journal:  BMC Cancer       Date:  2010-06-13       Impact factor: 4.430

4.  GreenLight HPS 120-W laser photoselective vaporization of the prostate as early therapy for acute urinary retention in advanced prostate cancer patients.

Authors:  Dong Chen; Boxin Xue; Yuxi Shan; Dongrong Yang; Chuanyang Sun; Jie Gao
Journal:  Lasers Med Sci       Date:  2013-01-03       Impact factor: 3.161

5.  High incidence of urological complications in men dying from prostate cancer.

Authors:  Takashi Kobayashi; Tomomi Kamba; Naoki Terada; Toshinari Yamasaki; Takahiro Inoue; Osamu Ogawa
Journal:  Int J Clin Oncol       Date:  2016-06-04       Impact factor: 3.402

6.  Analysis of urological procedures in men who died from prostate cancer using a population-based approach.

Authors:  Kara Babaian; Matthew Truong; Jeremy Cetnar; Deanna S Cross; Fangfang Shi; Mark A Ritter; David F Jarrard
Journal:  BJU Int       Date:  2012-11-06       Impact factor: 5.588

Review 7.  Rationale for stereotactic body radiation therapy in treating patients with oligometastatic hormone-naïve prostate cancer.

Authors:  Onita Bhattasali; Leonard N Chen; Michael Tong; Siyuan Lei; Brian T Collins; Pranay Krishnan; Christopher Kalhorn; John H Lynch; Simeng Suy; Anatoly Dritschilo; Nancy A Dawson; Sean P Collins
Journal:  Front Oncol       Date:  2013-12-03       Impact factor: 6.244

8.  Survival from prostate cancer in England and Wales up to 2001.

Authors:  N W Clarke
Journal:  Br J Cancer       Date:  2008-09-23       Impact factor: 7.640

9.  Association of dental and periodontal status with bisphosphonate-related osteonecrosis of the jaws. A retrospective case controlled study.

Authors:  Marcin Kos
Journal:  Arch Med Sci       Date:  2014-02-23       Impact factor: 3.318

Review 10.  A comprehensive review of contemporary role of local treatment of the primary tumor and/or the metastases in metastatic prostate cancer.

Authors:  Fouad Aoun; Alexandre Peltier; Roland van Velthoven
Journal:  Biomed Res Int       Date:  2014-11-17       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.